Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it has launched the AVENIO Tumor Tissue CGP Kit. The Kit complements the current CGP portfolio offered by Roche and Foundation Medicine and allows laboratories to expand their oncology research in-house. Ultimately, a future version of the kit may lead to additional resources for clinicians to use in the diagnosis and treatment of cancer.
Roche launches comprehensive genomic profiling kit to expand access to personalised cancer research
October 26, 2021
Related blog posts
New drug shows promise for fighting both COVID-19 and cancer
November 15, 2022